A group of entities and individuals, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, have filed an amended Schedule 13G/A with the SEC, indicating they no longer beneficially own more than five percent of Avalo Therapeutics, Inc.'s common stock as of December 31, 2023. The filing, dated February 14, 2024, confirms that each reporting person within the group holds zero shares and has zero percent ownership of the class, signifying a complete divestment from Avalo Therapeutics. The entities and individuals are primarily organized under the laws of Delaware, with Shah and Koh being United States citizens. The filing ensures that the disposition of the shares is not for the purpose of changing or influencing the control of Avalo Therapeutics.

A group of entities and individuals, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, have filed an amended Schedule 13G/A with the SEC, indicating they no longer beneficially own more than five percent of Avalo Therapeutics, Inc.'s common stock as of December 31, 2023. The filing, dated February 14, 2024, confirms that each reporting person within the group holds zero shares and has zero percent ownership of the class, signifying a complete divestment from Avalo Therapeutics. The entities and individuals are primarily organized under the laws of Delaware, with Shah and Koh being United States citizens. The filing ensures that the disposition of the shares is not for the purpose of changing or influencing the control of Avalo Therapeutics.